The pharmaceutical giant, still riding high on the sales of Comirnaty and Paxlovid, is looking to a future of innovative oncology drugs and vaccines based on mRNA technology.
Tag Archive for: Paxlovid
A rebound of COVID-19 symptoms in some patients after taking Pfizer’s antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday.
Recent studies have shown that patients with weakened immune systems — which enables the virus that causes COVID-19 to remain longer in the body, copy itself, and continually change — may enable the development of new, slightly different versions of the virus (variants).
Company CEO Albert Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech but said he has not yet taken the new bivalent booster.
In an interview, WHO senior adviser Bruce Aylward warned that richer nations must not step back from tackling COVID-19 as a global problem now, ahead of future potential waves of infection.
Pfizer Inc said on Thursday it would supply up to 6 million courses of its COVID-19 antiviral treatment to NGO Global Fund for low- and middle-income countries that seeks to address worldwide disparities in COVID response.
The company has donated 100,000 courses of its COVID-19 antiviral treatment Paxlovid to a new group aiming to improve access to the drug in low and middle-income countries.
In a recent large-scale study, Pfizer’s Paxlovid (nirmatrelvir and ritonavir tablets) appeared to be far more effective at reducing deaths and hospitalizations in older adults than younger patients stricken with the Omicron variant of COVID-19.
The U.S. Food and Drug Administration (FDA) has asked Pfizer Inc. to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.
Researchers at Case Western University looked at the real-world experiences of 13,644 patients who were treated with Paxlovid or Lagevrio (molnupiravir) during the first half of 2022. The study was intended to determine the prevalence of three types of rebound outcomes with these two therapies, each of which has emergency use authorizations as treatments for COVID-19. In that study (currently in preprint on medRxiv, co-author Pamela Davis, M.D. and colleagues found that the 7-day and 30-day rebound rates associated with Paxlovid treatments, respectively, were 3.53% and 5.4% for COVID-19 reinfection; 2.31% and 5.87% for COVID-19 symptoms; and 0.44% and 0.77% for hospitalizations.
